Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis

Clinical Infectious Diseases

Volumn 47, Issue 4, 2008, Pages 503-509

  Chamilos, Georgios ^a   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; POSACONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DISEASE CLASSIFICATION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTOPENIA; MORTALITY; MUCORMYCOSIS; MULTIVARIATE ANALYSIS; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK FACTOR; SALVAGE THERAPY; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; THERAPY DELAY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ROC CURVE; TIME FACTORS; ZYGOMYCOSIS;

EID: 48749096676     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590004     Document Type: Article

References (24)

1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
2. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20:581-607.
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-53.
4. Kontoyianis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
6. Park BJ, Pappas P, Marr KA, et al. Recent epidemiology of zygomycosis (ZM) among organ transplant (OTR) and stem cell transplant (SCT) recipients: results from the TRANSNET surveillance network [abstract M618]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007:434.
7. Marty EM, Cosimi L, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem cell transplants. N Engl J Med 2004; 350:950-2.
8. Siwek GT, Dodgson KJ, De Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7.
9. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-6.
10. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
11. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-5.
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
13. Kang CI, Kim SH, Park SW, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51.
14. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9.
15. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
16. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
17. Verweij PE, van Die L, Donelly JP. Halo sign and improved outcome. Clin Infect Dis 2007; 44:1666-7.
18. von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62:341-7.
19. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44:373-9.
20. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-9.
21. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159:1301-9.
22. Pagano L, Offidani M, Fianchi L, et al. GIMEMA infection program: mucormycosis in hematologic patients. Haematologica 2004; 89:207-14.
23. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-40.
24. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45:e101-4.